close

Global IT outage update - Monday 22 July

The issues affecting the supplier that provides our chemotherapy and immunotherapy treatments have now been resolved.

We want to thank our patients for being understanding and bearing with us and we apologise for any delays caused by this. Unless our teams contact you, please attend your appointment as planned. Throughout this incident, we have prioritised the most clinically urgent patients.

The Christie provides care and treatment for hundreds of people every day. The global IT outage last Friday (19 July 2024) affected many organisations but to put it into context, this affected less than a third of our patients.

Our staff have worked tirelessly over the weekend to deliver as many chemotherapy and immunotherapy treatments as possible and continue to do so to catch up on rescheduled treatments this week.

Skip to Content

Other publications - Michael Braun

Chester J, Joel SP, Cheeseman SL, Hall GD, Braun MS, Perry J, Davis T, Button CJ and Seymour MT. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fluorouracil-refractory metastatic colon cancer. Journal of Clinical Oncology, 21:1125-1132, 2003

Braun MS, Adab F, Bradley C, McAdam K, Thomas G, Wadd NJ, Rea D, Philips R, Twelves C, Bozzino J, MacMillan C, Saunders MP, Counsell R, Anderson H, McDonald A, Stewart J, Robinson A, Davies S, Richards FJ and Seymour MT. The Modified de Gramont with Oxaliplatin regimen in the first line treatment of advanced colorectal cancer. British Journal of Cancer 89:1155-8, 2003

Braun, Michael S; Quirke, Philip; Seymour, Matthew T. Molecular markers of chemotherapeutic response and toxicity in colorectal cancer. Expert Review of Anticancer Therapy, Volume 7, Number 4, April 2007 , pp. 489-501(13)

Michael S. Braun, Susan D. Richman, Philip Quirke, Catherine Daly, Julian W. Adlard, Faye Elliott, Jennifer H. Barrett, Peter Selby, Angela M. Meade, Richard J. Stephens, Mahesh K. B. Parmar and Matthew T. Seymour, on behalf of the MRC FOCUS (CR08) trial collaborators and the National Cancer Research Institute Colorectal Clinical Studies Group. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from a large randomized trial. J Clin Oncol. 2008 Jun 1;26(16):2690-8.

Michael S. Braun, Susan D. Richman, Lindsay Thompson, Catherine Daly, Angela Meade, Julian W. Adlard, James M. Allan, Mahesh K. B. Parmar, Phil Quirke, Matthew T. Seymour on behalf of the MRC CR08 (FOCUS) trial collaborators. Association of Molecular Markers with Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer (FOCUS Trial). Accepted for publication in J Clin Oncol March 2008.

M.S.Braun and C.J.Twelves. Capecitabine in Colorectal Cancer. Therapy, March 2009, Vol 6, No. 2, pg 239-248.

Michael S Braun and Matthew T Seymour. Molecular Markers of Chemotherapy Response in Colorectal Cancer. Curr Colorectal Cancer Rep, 2010, 6: 118-125

FOXTROT Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012 Nov;13(11):1152-60

D. Rosmarin, C Palles, D. Church, E. Domingo, A. Jones, QUASAR2 collaborators, H. Wang, E. Johnsone, G. Nicholson, A. Gonzalez-Neira, D. Sargent, E. Green, H. McLeod, U. Zanger, M. Schwab, M. Braun, M. Seymour, L. Thompson, J-P. Pignon, B. Lacas, V. Boige, N Ribelles, S. Afzal, M-C Etienne-Grimaldi, G. Milano, M. Wadelius, H. Garmo, M. Gusella, T. Lecomte, P. Laurent-Puig, E. Martinez-Balibrea, R. Sharma, J. Garcia-Foncillas, A. Morel, Z. Kleibl, R. Midgley, D. Kerr, I. Tomlinson. Genetic markers of toxicity from Capececitabine and other 5-Fluorouracil based regimens: investigation in the QUASAR2 study, systematic review and meta-analysis. J Clin Oncol. 2014 Apr 1;32(10):1031-9

Last updated: January 2023